DOI: https://doi.org/10.22263/2312-4156.2016.1.7
Петрович Д.М.*, Кундер Е.В.*, Волкова М.В.**
Взаимосвязь спондилоартритов и воспалительных заболеваний кишечника
*ГУО «Белорусская медицинская академия последипломного образования», г. Минск, Республика Беларусь
**УО «Витебский государственный ордена Дружбы народов медицинский университет», г.Витебск, Республика Беларусь
Вестник ВГМУ. – 2016. – Том 15, №1. – С. 7-18.
Резюме.
Публикации последнего десятилетия отражают ренессанс проблемы изучения взаимоотношений между спондилоартритами и воспалительными заболеваниями кишечника. Кишечное воспаление наиболее часто является первичным процессом и предшествует спондилоартриту. Основными событиями иммунопатогенеза считается миграция иммунных клеток из лимфоидных структур кишечника в синовиальную ткань, презентация артритогенных структур и активация иммунного воспаления в синовии. В патологический процесс вовлекается сходный спектр провоспалительных цитокинов.
В обзоре представлены современные сведения о взаимосвязях спондилоартритов и воспалительных заболеваний кишечника. Обсуждаются новые возможности лабораторного обследования пациентов для прогнозирования развития воспалительного процесса в кишечнике и опорно-двигательном аппарате, а также оценки активности воспаления. Проанализированы возможности высокотехнологичного лечения воспалительных заболеваний кишечника и спондилоартритов.
Ключевые слова: спондилоартриты, воспалительные заболевания кишечника, аутоантитела.
Литература
1. High frequency of silent inflammatory bowel disease in spondyloarthropathy / M. Leirisalo-Repo [et al.] // Arthritis Rheum. – 1994 Jan. – Vol. 37, N 1. – P. 2331.
2. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease / N. Turkcapar [et al.] // Rheumatol. Int. – 2006 May. – Vol. 26, N 7. – P. 663–668.
3. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects / H. Mielants [et al.] // J. Rheumatol. – 1995 Dec. – Vol. 22, N 12. – P. 2273–2278.
4. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joints / H. Mielants [et al.] // J. Rheumatol. – 1995 Dec. – Vol. 22, N 12. – P. 2274–2284.
5. Common immunologic mechanisvs in inflammatory bowel disease and spondyloarthropathies / M. C. Fantini [et al.] // World J. Gastroenterol. – 2009 May. – Vol. 15, N 20. – P. 2472–2478.
6. Clinical features of imflammatory joint and spine manifestations in Crohn’s disease / H. Munch [et al.] // Hepatogastroenterology. – 1986 Jun. – Vol. 33, N 3. – P. 123–127.
7. Articular manifestations in inflammatory bowel disease patients: a prospective study / R. D’Incà [et al.] // Dig. Liver Dis. – 2009 Aug. – Vol. 41, N 8. – P. 565–569.
8. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease / A. Beslek [et al.] // Rheumatol. Int. – 2009 Jun. – Vol. 29, N 8. – P. 955–957.
9. Rebello, A. Association of ankylosing spondylitis and Crohn’s disease successfully treated with infliximab / A. Rebello, S. Leite, J. Cotter // BioDrugs. – 2010 Dec. – Vol. 24, suppl. 1. – P. 37–39.
10. The joint-gut axis in inflammatory bowel diseases / L. K. Brakenhoff [et al.] // J. Crohns Colitis. – 2010 Sep. – Vol. 4, N 3. – P. 257–268.
11. Psoriasis, psoriatic arthritis and increased risk of incident Crohn’s disease in US women / W. Q. Li [et al.] // Ann. Rheum. Dis. – 2013 Jul. – Vol. 72, N 7. – P. 1200–1205.
12. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort / S. R. Vavricka [et al.] // Am. J. Gastroenterol. – 2011 Jan. – Vol. 106, N 1. – P. 110–119.
13. Abraham, C. Inflammatory bowel diseases / C. Abraham, J. H. Cho // N. Engl. J. Med. – 2009 Nov. – Vol. 361, N 21. – P. 2066–2078.
14. Cho, J. H. The genetics and immunopathogenesis of inflammatory bowel diseases / J. H. Cho // Nat. Rev. Immunol. – 2008 Jun. – Vol. 8, N 6. – P. 458–466.
15. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms / F. Van den Bosch [et al.] // Lancet. – 2000 Nov. – Vol. 356, N 9244. – P. 1821–1822.
16. Rimbras, M. Bowel lesions in spondyloarthritides // M. Rimbas, M. Marinescu, M. R. Voiosu // Rom. J. Intern. Med. – 2009. – Vol. 47, N 1. – P. 75–85.
17. Campbell, D. J. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues / D. J. Campbell, E. C. Butcher // J. Exp. Med. – 2002 Jan. – Vol. 195, N 1. – P. 135–141.
18. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow / C. Berlin [et al.] // Cell. – 1995 Feb. – Vol. 80, N 3. – P. 413–422.
19. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MadCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease / H. S. Souza [et al.] // Gut. – 1999 Dec. – Vol. 45, N 6. – P. 856–863.
20. Gut associated lymphoid tissue-primed CD4+ T cells display CC9-dependent and -independent homing to the small intestine / H. Stenstad [et al.] // Blood. – 2006 May. – Vol. 107, N 9. – P. 3447–3454.
21. Salmi, M. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD / M. Salmi, S. Jalkanen // Inflamm. Bowel Dis. – 1998 May. – Vol. 4, N 2. – P. 149–156.
22. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 pransgenic rats / J. D. Taurog [et al.] // Exp. Med. – 1994 Dec. – Vol. 180, N 6. – P. 2359–2364.
23. Rath, H. C. Differential induction of colitis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli / H. C. Rath, K. H. Wilson, R. B. Sartor // Infect. Immun. – 1999 Jun. – Vol. 67, N 6. – P. 2969–2974.
24. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects / H. Mielants [et al.] // J. Rheumatol. – 1995 Dec. – Vol. 22, N 12. – P. 2266–2272.
25. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study) / O. Palm [et al.] // J. Rheumatol. – 2002 Mar. – Vol. 29, N 3. – P. 511–515.
26. Kuon, W. Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algoriths and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis / W. Kuon, J. Sieper // Rheum. Dis. Clin. Nirh. Am. – 2003 Aug. – Vol. 29, N 3. – P. 595–611.
27. Analysis of the antigen-specific T cell response in reactive arthritis by fpow cytometry / A. Thiel [et al.] // Arthritis Rheum. – 2000 Dec. – Vol. 43, N 12. – P. 2834–2842.
28. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope / O. Cohavy [et al.] // Infect. Immun. – 2000 Mar. – Vol. 68, N 3. – P. 1542–1548.
29. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins / M. Ramos [et al.] // J. Biol. Chem. – 2002 Oct. – Vol. 277, N 40. – P. 37573–37581.
30. Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study / M. L. Mundswiler [et al.] // Arthritis Res. Ther. – 2009. – Vol. 11, N 6. – P. R177.
31. Regulation of gut inflammation and th17 cell response by interleukin-21 / D. Fina [et al.] // Gastroenterology. – 2008 Apr. – Vol. 134, N 4. – P. 1038–1048.
32. Increased number of circulating polyfunctional Th17 memory cells in patients with seronegativespondyloarthritides / C. Jandus [et al.] // Arthritis Rheum. – 2008 Aug. – Vol. 58, N 8. – P. 2307–2317.
33. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene / R. H. Duerr [et al.] // Science. – 2006 Dec. – Vol. 314, N 5804. – P. 1461–1463.
34. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies / D. Kontoyiannis [et al.] // Immunity. – 1999 Mar. – Vol. 10, N 3. – P. 387–398.
35. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases / M. Armaka [et al.] // J. Exp. Med. – 2008 Feb. – Vol. 205, N 2. – P. 331–337.
36. Mucosal inflammation in spondylarthritides: past, present, and future / L. Van Praet [et al.] // Curr. Rheumatol. Rep. – 2011 Oct. – Vol. 13, N 5. – P. 409–415.
37. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model / L. Van Prae [et al.] // Ann. Rheum. Dis. – 2013 Mar. – Vol. 72, N 3. – P. 414–417.
38. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study / W. J. Sandborn [et al.] // Clin. Gastroenterol. Hepatol. – 2006 Feb. – Vol. 4, N 2. – P. 203–211.
39. Mielants, H. Ankylosing spondylitis and reactive arthritis: pathogenic aspects and therapeutic consequenses / H. Mielants. – Ghent : Chent University, 1988. – 357 p.
40. Association of macroscopic gut inflammation with disease activity, functional status and quality of life in ankylosing spondylitis / G. Hascelik [et al.] // Rheumatol. Int. – 2009 May. – Vol. 29, N 7. – P. 755–758.
41. Psoriasis, the liver, and the gastrointestinal tract / P. Gisondi [et al.] // Dermatol. Ther. – 2010 Mar-Apr. – Vol. 23, N 2. – P. 155–159.
42. Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease / R. Perez Alamino [et al.] // J. Rheumatol. – 2011 Aug. – Vol. 38, N 8. – P. 1656–1660.
43. Sundström, B. Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis / B. Sundström, S. Wållberg-Jonsson, G. Johansson // Clin. Rheumatol. – 2011 Jan. – Vol. 30, N 1. – P. 71–76.
44. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy / I. E. Hoffman [et al.] //Ann. Rheum. Dis. – 2003 May. – Vol. 62, N 5. – P. 455–459.
45. Rimbras, M. Bowel lesions in spondyloarthritides / M. Rimbas, M. Marinescu, M. R. Voiosu // Rom. J. Intern. Med. – 2009. – Vol. 47, N 1. – P. 75–85.
46. Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA / H. P. Torok [et al.] // Digestion. – 2004. – Vol. 70, N 1. – P. 49–54.
47. Anti-Saccharomyces cerevisiae (ASCA) and anti-endomysial antibodies in spondyloarthritis / M. A. Andretta [et al.] // Rheumatol. Int. – 2012 Feb. – Vol. 32, N 2. – P. 551–554.
48. Glycoprotein 2 antibodies in Crohn’s disease / D. Roggenbuck [et al.] // Adv. Clin. Chem. – 2013. – Vol. 60. – P. 187–208.
49. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations / S. Generini [et al.] // Ann. Rheum. Dis. – 2004 Dec. – Vol. 63, N 12. – P. 1664–1669.
50. Differences in the incidence of flares or the new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factorn alpha agents / J. Braun [et al.] // Arthritis Rheum. – 2007 May. – Vol. 57, N 4. – P. 6339–6347.
51. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maimtained for up to 2 years: long-term results from ATLAS trial / D. Van der Heijde [et al.] // Ann. Rheum. Dis. – 2009 Jun. – Vol. 68, N 6. – P. 922–929.
52. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial / D. van der Heijde [et al.] // Arthritis Rheum. – 2006 Jul. – Vol. 54, N 7. – P. 2136–2146.
Сведения об авторах:
Петрович Д.М. – соискатель кафедры кардиологии и ревматологии ГУО «Белорусская государственная медицинская академия последипломного образования»;
Кундер Е.В. – д.м.н., профессор кафедры кардиологии и ревматологии ГУО «Белорусская государственная медицинская академия последипломного образования»;
Волкова М.В. – к.м.н., доцент кафедры внутренних болезней №2 УО «Витебский государственный ордена Дружбы народов медицинский университет».
Адрес для корреспонденции: Республика Беларусь, 210023, г. Витебск, пр. Фрунзе, 27, УО «Витебский государственный ордена Дружбы народов медицинский университет», кафедра внутренних болезней №2. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Волкова Маргарита Васильевна.
